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Eukaryotic cells have developed elaborate mechanisms of mRNA quality control that 
secure gene expression fidelity through the detection and degradation of abnormal 
transcripts. NMD (nonsense-mediated mRNA decay), which detects and degrades 
transcripts containing premature translation termination codons (PTCs), and NSD (nonstop 
mRNA decay), that detects and degrades transcripts without in-frame stop codons, are just 
two examples. Nonsense-mediated mRNA decay (NMD) in particular, is a conserved 
surveillance system in all eukaryotic cells and is also the most extensively studied. PTC-
containing mRNAs could, without NMD, give rise to C-terminally truncated proteins toxic 
for the cell. The physiological importance of NMD is further manifested by the fact that 
about one third of genetic disease-associated mutations generate PTCs. Recently, some 
studies have shown that aminoglycosides, low molecular weight compounds, and non -
aminoglycosides can suppress PTCs in cystic fibrosis, Duchenne’s muscular dystrophy 
others, as a novel therapeutic approach, suppression therapy, which uses these 
compounds to induce recoding of a PTC into a sense codon. It is unclear whether β-
thalassaemia would also be responsive to suppression therapy. Some recent studies show 
positive results for the compound PTC124 in suppressing nonsense mutations  in the CFTR 
gene and others; also preliminary results obtained in our lab have shown that the 
aminoglycoside G418 can suppress a nonsense mutation at codon 39 of the human β -
globin mRNA, although at low levels in cultured erythroid cells. As a first part of this work, 
we decided to investigate if suppression therapy can restore enough β-globin protein to 
correct the disease manifestations of β-thalassaemia. We intended to test whether G418 
and/or PTC124 were able to induce efficient levels of suppression in a dose -dependent 
manner in HeLa cells transfected with plasmids containing the human β-globin wild type 
gene (βWT) or the other variants carrying a nonsense mutation at codon 15 (β15) or 39 
(β39). However, we weren’t successful in this approach due to difficulties in gene cloning.  
The next step for RNAs targeted by NMD or NSD, as well as normal transcripts, which don’t 
accumulate indefinitely, is degradation. Generally the exosome complex, a multi-subunit 
ribonuclease complex, is responsible for the 3’-5’ degradation of every type of RNA in the 
cell, with its main catalytic component being either Dis3 or Dis3L1 in humans. However, 
another ribonuclease has been identified: DIS3L2. This protein is thought to be a 
XVI 
 
cytoplasmic exosome-independent 3’-5’ ribonuclease, with special affinity for urydilated 
transcripts. Nonetheless, not much else is known for certain about its activity, especially in 
humans, including if it is coupled to NMD or NSD mRNA degradation. As a consequence, 
we intended to evaluate hDIS3L2’s possible involvement in mRNA degradation pathways , 
by performing knockdown of hDIS3L2, with siRNAs (small-interfering RNAs) in HeLa cells 
transfected with plasmids containing the human β-globin wild type gene (βWT), the 
variants carrying a nonsense mutation at codon 15 (β15), 26 (β 26) or 39 (β39), and also a 
variant lacking an in-frame stop codon (nonstop) (βNS). We then evaluated the human β-
globin mRNA levels, as well as HFE’s, which is an NMD natural target. Our results show 
that human DIS3L2 is involved in NMD, NSD and possibly normal transcript degradation  
(mRNA turnover). 
 



























A expressão génica nos eucariotas envolve uma série  de passos interligados e acoplados 
entre si, tendo a molécula de RNA (ribonucleic acid) como mensageiro entre os grandes 
passos. Resumidamente, a mensagem codificada pelas bases nucleotídicas do ácido 
desoxirribonucleico (DNA) (deoxyribonucleic acid) é transferida para uma molécula de RNA 
(transcrição), que, após processamento no núcleo, é transferida para o citoplasma onde é 
lida e transformada numa cadeia polipeptídica (tradução). Por vezes, contudo, podem 
ocorrer erros, em qualquer uma das fases da expressão, erros esses que podem resultar 
em mRNAs aberrantes que, se forem traduzidos, podem dar origem a proteínas truncadas 
com possíveis efeito deletérios. Para contornar este problema, as células eucarióticas 
desenvolveram mecanismos de controlo de qualidade do mRNA de modo a assegurarem a 
fidelidade da expressão génica através da detecção e degradação de transcritos 
aberrantes. O decaimento do mRNA mediado por mutações nonsense (NMD; Nonsense-
mediated mRNA decay) é o mais conhecido, detecta e degrada transcritos que contêm 
codões de terminação prematuros (CTPs). O decaimento nonstop (NSD; Nonstop mRNA 
decay) detecta e degrada transcritos que não possuem codões de terminação em fase  na 
grelha de leitura, mas existem outros, como o NGD (No-go decay) que evoluiu para lidar 
com os transcritos que possuem uma qualquer mutação que impeça a normal elongação 
da tradução. O NMD em particular, é um mecanismo de vigilância conservado em todas as 
células eucarióticas e é também o mais estudado. Os mRNAs que contêm CTPs  poderiam 
dar origem, sem o NMD, a proteínas truncadas na extremidade C-terminal tóxicas para a 
célula, que podem adquirir um ganho de função prejudicial ou um efeito dominante-
negativo. A importância fisiológica do NMD é ainda adicionalmente demonstrada pelo 
facto de que cerca de um terço das doenças genéticas associadas a doenças gerarem CTPs. 
Recentemente, alguns estudos têm vindo a demonstrar que compostos de baixo peso 
molecular, aminoglicósidos e não-aminoglicósidos podem suprimir CTPs em contexto de 
fibrose cística, distrofia muscular de Duchenne e difeciência em carnitina 
palmitoltransferase 1A como uma nova abordagem terapêutica, a terapia de supressão, a 
qual usa estes compostos para induzir a recodificação de um codão nonsense num codão 
sense. Uma doença também associada a mutações nonsense é a β-talassémia. A β-
talassémia é uma das doenças genéticas mais comuns no mundo e cujo tratamento para 
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os fenótipos mais agressivos requer inevitavelmente transfusões regulares sanguíneas, 
com os riscos que isso acarreta como a acumulação excessiva de ferro no organismo. Uma 
cura que se possa chamar definitiva ainda não existe e, portanto, qualquer nova 
abordagem terapêutica constitui uma mais valia. O NMD é um modelador do fenótipo da 
β-talassémia, podendo contribuir para o melhoramento das manifestações da doença. Em 
relação à terapia de supressão, permanece ainda por esclarecer se a β-talassémia 
responderia também à mesma. Alguns estudos recentes mostram resultados positivos 
para o composto PTC124 (ou Ataluren) na supressão de mutações nonsense no gene da 
CFTR (associadas à Fibrose Cística) bem como noutros genes, associados à Distorifia 
Muscular de Duchenne, Síndrome de Usher e Defeciência em Carnitina Palmitoltransferase 
1C; para além disso, resultados obtidos previamente pelo nosso laboratório demonstraram 
que o aminoglicósido G418 pode suprimir uma mutação nonsense no codão 39 do mRNA 
do gene da β-globina humana, embora a baixos níveis em células eritróides em cultura. 
Tendo em conta esta informação, como uma primeira parte deste trabalho, decidimos 
investigar se a terapia de supressão pode restaurar β-globina suficiente para conseguir 
corrigir as manifestações da β-talassémia. Propusémo-nos a testar se o G418 e/ou o 
PTC124 seriam capazes de induzir níveis suficientes de supressão, duma maneira 
dependente da dose, em células HeLa transfectadas com plasmídeos que contêm o gene 
da β-globina humana, variante selvagem, wild type (βWT), ou as outras variantes contendo 
uma mutação nonsense no codão 15 (β15) ou 39 (β39). Contudo, não fomos bem 
sucedidos nesta primeira parte do projecto devido a dificuldades intransponíveis 
associadas à clonagem de genes. 
O próximo passo para os RNAs sinalizados pelas maquinarias do NMD ou do NSD, bem 
como os RNAs normais, que não se acumulam indefinidamente, é a degradação. A 
degradação é, na verdade, uma parte essencial do metabolismo do mRNA,  constituindo 
até um mecanismo pelo qual a expressão génica é regulada. Na degradação do mRNA, o 
exossoma é um componente essencial. O exossoma eucariótico é um complexo 
ribonucleolítico multi-subunidade, e é responsável pela degradação na direcção 3’ -5’ de 
todos os tipos de RNA na célula, entre outras coisas. As proteínas humanas Dis3 ou Dis3L1 
são os seus elementos catalíticos. Contudo, outra ribonuclease foi também identificada, a 
Dis3L2, da qual pouco ainda se sabe, especialmente em humanos. Pensa-se que esta 
proteína seja uma ribonuclease citoplasmática na direcção 3’-5’, independente do 
exossoma, que parece ter especial afinidade para transcritos uridilados. Tendo em conta 
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as lacunas no conhecimento acerca da Dis3L2 humana (hDis3L2) e da importância dos 
mecanismos de vigilância do mRNA e da sua degradação, decidimos avaliar a possibilidade 
da Dis3L2 humana estar efectivamente envolvida nas vias de degradação do mRNA NMD 
e/ou NSD. Para esse efeito, foram efectuadas experiências de silenciamento do gene da 
Dis3L2 humana recorrendo à tecnologia de RNA de interferência, mais especificamente 
siRNAs (small interfering RNAs) em células HeLa transfectadas com plasmídeos contendo a 
variante selvagem do gene da β-globina humana (βWT), com as variantes contendo uma 
mutação nonsense no codão 15 (β15), 26 (β26) ou 39 (β39), e também a variante que não 
contém um codão de terminação na grelha de leitura, nonstop, (βNS). Seguidamente 
avaliámos os níveis celulares de mRNA da β-globina humana, bem como os do HFE, que é 
um alvo natural do NMD. Os nossos resultados sugerem que a hDis3L2 está envolvida no 
NMD, NSD e possivelmente também na degradação de transcritos normais e 
consequentemente no turnover do RNA. 
 
Palavras-chave: Decaimento do mRNA mediado por mutações nonsense (NMD); 









































1.1. Gene Expression in Eukaryotes 
The central dogma of molecular biology states that protein synthesis starts with 
transcription of a DNA template into a complementary messenger RNA molecule (mRNA) 
in the nucleus of the eukaryotic cell, which is then transported to the cytoplasm where it 
will be translated into protein by the ribosomes1. This seemingly straightforward 
mechanism involves, in reality, a series of interconnected steps and a complex coupled 
network of machineries that guarantees the efficiency and specificity of gene expression, 
with messenger RNAs being the key intermediaries throughout the whole process2,3. 
Briefly, the DNA is transcribed into a precursor mRNA (pre-mRNA) molecule by the 
ribosome, to which a 5’cap and a 3’poly(A) tail will be added mainly for protection against 
degradation. Also this pre-mRNA molecule will be subject to splicing, which consists in 
removing introns and joining together the exons. By the  end of this stage we have a 
mature mRNA molecule. This mRNA is transported to the cytoplasm where it will finally be 
translated into protein and eventually degraded3,4. 
However, sometimes errors occur, at any step of gene expression, and aberrant mRNAs 
are produced4. If translated, these result in aberrant proteins that can be detrimental to 
the cell5. To deal with this problem, evolution came up with mRNA surveillance 
mechanisms. These mechanisms target and degrade aberrant transcripts before they can 
be translated thus avoiding the possible deleterious effects of aberrant proteins. There are 
three main mRNA surveillance pathways, although they are not the only ones, which are: 
Nonsense-Mediated Decay (NMD), Nonstop Decay (NSD) and No-Go Decay (NGD); they 
target and degrade, respectively, transcripts containing a premature termination codon 
(PTC), mRNAs lacking a termination codon and mRNAs containing any mutation that stalls 
the ribosome and impedes normal translation elongation6. Of these three pathways, NMD 
and NSD are the ones relevant for this study. 
 
1.2. mRNA Translation 
One of the most important steps in mRNA life and gene expression is the translation  of 
messenger RNA into protein. Like virtually all the steps in gene expression, mRNA 
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translation is a tightly regulated process, aiding the fine tuning of eukaryotic gene 
regulation7. In order to better understand the translation-dependent mechanisms of NMD 
and NSD, as well as gene therapy itself, it is useful to get familiar with the basic concepts 
of mRNA translation. 
Translation is conceptually divided into three stages (initiation, elongation and 
termination) where the codon sequence in the mRNA directs the synthesis of a 
polypeptide chain, with ribosomes, which are two-subunit ribonucleoproteins, being the 
key players in the reaction8,9,10. The three stages are explained bellow. 
 
1.2.1. Translation Initiation 
In the canonical, cap-dependent, mechanism of translation, the interaction of the ternary 
complex with the 40S ribosomal subunit marks the beginning. This complex is formed by 
the eukaryotic initiation factor eIF2 bound to both the methionyl-initiator tRNA (Met-
tRNAi
Met) and GTP11. When the ternary complex, along with eIF1, 1A, 3 and 5, binds to the 
40S ribosomal subunit, the 43S pre-initiation complex (PIC) is formed7,11,12,13. This complex, 
according to Kozak’s scanning model  has the task of scanning the 5’UTR (5’ untranslated 
region) until it finds the AUG initiation codon, where translation starts14. But before that 
happens, another complex must be present: eIF4F. The eukaryotic initiation factor 4F 
recognizes the 5’-cap proximal region of mRNA and its functions are illustrated by each of 
its three comprising elements: the ATP-dependent DEAD-box RNA-helicase eIF4A, which 
resolves secondary structures in the 5’UTR, making the scanning process possible; eIF4E 
which is the cap-binding element; and eIF4G that acts as a scaffold protein for the 
interaction of the other two and also interacts with the poly(A)-binding protein (PABP) and 
by doing so, circularizes the mRNP (messenger ribonucleoprotein)  molecule, because PABP 
is bound to the 3´-poly(A)-tail15,16,17. 
When both complexes, eIF4F and PIC, are present and bound to their respective targets, 
scanning, by PIC, of the 5’UTR in the 5’-3’ direction takes place until it finds an AUG codon 
in an optimum context, which is the start codon. When this happens, complementary base 
pairing takes place between the start codon, which by now is at the peptidyl-tRNA (P) site 
of the 40S subunit, and the anticodon present in the Met-tRNAi
Met. Then, eIF5 activates 
GTPases, which hydrolyze the ternary complexes’ GTP bound to the eIF2 and this triggers 
the displacement of the initiation factors, eventually leading to the joining of the 60S 
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ribosomal subunit, catalyzed by eIF5B. The 80S eukaryotic ribosome is formed and the 
translation initiation phase has ended18,19,20. The entire process is pictured in figure 1. 
  
Figure 1 – Canonical model of cap-dependent translation initiation. A: The ternary 
Complex (TC) binds to the 40S ribosomal subunit, along with eIF1, 1A, 3 and 5 forming the 43S pre-
initiation complex (PIC). B: Also, eIF4F recognizes the 5’-cap proximal region of mRNA and interacts with 
PABP via the eIF4G element. C: When both eIF4F and PIC are bound to the mRNP, PIC scans the 5’UTR in 
the 5’-3’ direction until  it finds the AUG initiation codon. D: The start codon is recognized, 
complementary base pairing takes place between the nucleotide elements of the Met-tRNAi
Met
  and the 
mRNP. Then, eIF5 activates GTPases, which hydrolyze the ternary complexes’ GTP bound to the eIF2, 
triggering the displacement of the initiation factors. E: Joining of the 60S ribosomal subunit to the 40S 
takes place, catalyzed by eIF5B. The 80S eukaryotic ribosome is formed and the translation initiation 










1.2.2. Translation Elongation 
This stage consists of the sequential decoding of the mRNA nucleotide sequence, in the 5’ -
3’ direction, into a polypeptide chain21,22; the order of the mRNA codons specifies the 
order in which amino acids are added23. 
By the end of initiation, we are left with the initiator aminoacyl-tRNA located at the P-site 
of the ribosome, base-paired with the start codon, and the adjacent A-site empty and 
ready to receive a cognate aminoacyl-tRNA, thereby continuing the decoding process of 
mRNA into protein10,11,18,24. In this sequential process, the eukaryotic elongation factor 
eEF1A has the task of bringing the aminoacyl-tRNAs to the ribosome A-site: if codon and 
anticodon are complementary, then eEF1A activates GTP hydrolysis, which in turn induces 
eEF1A release, thereby permitting the entry of aminoacyl-tRNA to the A site24,. Then, the 
two tRNAs present at the moment at the ribosome are translocated, thanks to the aid of 
the GTP-dependent eEF2: the deacylated tRNA is translocated from the P to the E-site (E 
from “exit”) and the peptidyl-tRNA from the A to the P-site (figure 2) and the ribosome 
moves 3 nucleotides in the 5’-3’ direction23. Also eEF1A interacts with eEF1B, which 
promotes the exchange of GDP for GTP, recycling the GTP-bound eEF1A23. After 
translocation, the A-site is once again empty and ready for the next aminoacyl-tRNA. This 




Figure 2 – Translation Elongation. Starting at the top: the elongation factor eEF1A brings the 
aminoacyl-tRNA to the ribosomal  A-site, where complementary base pairing occurs. Then eEF1A 
activates GTP hydrolysis, inducing eEF1A release, which allows the entry of the aminoacyl -tRNA to the A-
site. GDP is recycled to eEF1A-GTP by the exchange factor eEF1B. After the tRNA accommodation into 
the A-site, peptide bond formation occurs. Then, the two tRNAs present at the ribosome are 
translocated, by binding of the GTP-dependent eEF2. The ribosome is now ready for the next cycle of 
elongation with release of the deacylated tRNA from the E-site and binding of the appropriate eEF1A-
GTP-aminoacyl-tRNA to the A-site. In this figure GTP is depicted as a green circle and GDP as a red one. 
In Dever & Green (2012). 
 
1.2.3. Translation Termination 
Translation termination takes place when the ribosome recognizes a stop codon, making 
the whole translation process come to an end and the nascent protein is released25. It all 
starts when a stop codon, either UAG, UGA or UAA, is present at the A-site. Because there 
is no cognate aminoacyl-tRNA for a stop codon, the ribosome stalls and eRF1 recognizes 
the stop codon instead and also forms a complex with the GTPase eRF3, which causes GTP 
hydrolysis. This hydrolysis, in turn, induces a conformational change in eRF1 that allows it 
to move closer to the P-site and promote cleavage of the peptidyl-tRNA ester bond, finally 
leading to the release of the newly synthesized polypeptide chain23,26,27 and both ribosome 




Figure 3 – Translation Termination. From left to right, when a stop codon, UAG, UGA or UAA, 
is present at the A-site, the ribosome stalls and eRF1, complexed with the GTPase eRF3, recognizes the 
stop codon, which causes GTP hydrolysis. This hydrolysis induces a conformational change in eRF1 that 
allows it to move closer to the P-site and promote cleavage of the peptidyl -tRNA ester bond, leading to 
the release of the newly synthesized polypeptide chain. Adapted from Keelint et al. (2014). 
 
 
1.3. Nonsense Mediated mRNA Decay 
NMD is a post-translational surveillance mechanism that is evolutionary conserved in 
eukaryotic cells. It is also the most studied quality control mechanism in eukaryotes6. 
Briefly, NMD function is to identify and eliminate mRNAs that contain premature 
translation termination codons (PTCs), also known as nonsense codons, thus preventing 
the synthesis and accumulation of C-terminally truncated proteins that can have a 
dominant-negative or gain-of-function effect potentially deleterious for the cell4,26,29,30,31. It 
is important to note, however, that in mammals there are other quality control 
mechanisms, such as NSD (nonstop mRNA decay), which we will also approach in this 
work, and NGD (no-go mRNA decay) 8,6. In order to understand the type of gene therapy 
that we tried to achieve in this work, which was one where we used the knowledge of the 
NMD mechanism to our advantage, one must first comprehend NMD itself.  
 
1.3.1. PTC Recognition and NMD Eliciting 
Generally, PTCs can arise from nonsense or frameshift mutations in the DNA sequence, 
transcription errors, anomalous splicing events, among others31,32,33. When these PTCs are 
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located at more than 50-55 (or 50-54 depending on the references; for convenience 
purposes, we will refer to this boundary as 50-55) nucleotides (nts) upstream the last 
exon-exon junction, they are indeed recognized as what they are, aberrant stop codons, 
and are thus able to elicit NMD, but if they are located downstream of this boundary, NMD 
is not elicited4,27,32. This happens as such because, when pre-mRNA splicing occurs in the 
nucleus of the eukaryotic cell, multiprotein complexes appropriately called exon junction 
complexes (EJCs) are deposited  approximately 20-24 nts upstream of each exon-exon 
junction. During the pioneer round of translation, the 80S ribosome displaces the EJCs 
assembled in the open reading frame (ORF), but, if the transcript has a PTC positioned at ≥ 
50-55 nts upstream the last exon-exon junction, the ribosome will reach a stop codon 
(which is, obviously, premature in this case) before it actually can be in a close enough 
position to displace the next EJC (figure 4) and therefore, the EJC will not be removed as it 
normally would34,35. The EJC will trigger recruitment the NMD factors UPF3 and UPF2, 
which may be attributable to the MAGOH/Y14 heterodimer (a component of the EJC) 31,36. 
It has been shown, however, that AUG-proximal PTCs fail to elicit NMD, in spite of fulfilling 
the rule of being positioned at ≥ 50-55 nts upstream the last exon-exon junction; this 
implies that the EJC-dependent model is not the only mechanism by which NMD is 
triggered32,37. How is NMD elicited then? Work previously done in our lab, as well as other 
studies, have suggested that the mechanism behind this is a competitive relationship 
between PABP and UPF1 for binding eRF3. When PABP is in close proximity to a PTC 
(which happens when the PTC is AUG-proximal; this is made possible by the circular 
conformation of the mRNA), it interacts with the release factor eRF3 and promotes 
translation termination; however when the PTC is not physically close enough to PABP, 






Figure 4 - Simplified model of mammalian EJC-dependent NMD eliciting. On the 
left, a PTC is located more than 50-55 nts upstream the last exon-exon junction, therefore it will  elicit 
NMD and hence, degradation of the transcript will occur. On the right, there’s a PTC located within the 
50-55 nts boundary and as such it won’t be recognized by the NMD machinery and, as a consequence, 
that transcript won’t be rapidly degraded and will  result in a truncated protein. In the figure, “Ter” 
represents the canonical termination codon. In Khajavi et al. (2006). 
 
1.3.2. mRNA Degradation via NMD 
Following PTC recognition, the next step for the NMD machinery is the degradation of the 
faulty mRNA molecule. However, unlike the previous step, mRNA degradation via NMD is 
not a very well understood process to date; still, some studies did manage to provide 
insights and models. 
It is known that, in NMD, phosphorylated UPF1 has better affinity for RNA and marks the 
mRNA for degradation27,41. UPF1 phosphorylation occurs as follows: once UPF1 has been 
recruited to the terminating ribosome, as it has already been mentioned, it will interact 
with eRF3 and form the SURF complex (SMG1-UPF1-eRF1-eRF3)42. The SURF complex, via 
UPF1, binds to UPF2 and UPF3, the former, in turn, binds to the EJC; all these elements 
together constitute the DECID complex (Decay-Inducing Complex). Finally, the DECID 
complex promotes UPF1 phosphorylation by SMG143,44,45,46. This phosphorylated UPF1 
recruits either SMG6, which has endonucleolytic activity, or the SMG7/SMG5 
heterodimer46. 
If SMG6 is the one recruited and interacts with phosphorylated UPF1, endonucleolytic 
cleavage of the transcript in the vicinity of the PTC occurs by the action of SMG6 itself. This 
cleavage produces two cleavage products: one 3’ product, which contains the EJC and 
NMD components, and another 5’ product that includes the PTC. The 5’ cleavage product 
undergoes 3’-5’ degradation, as it seems, by the exosome, while the 3’ product is first 
stripped off of its proteins by the action of UPF1 (because when it binds UPF2, as is the 
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case in the DECID complex, UPF1’s helicase activity is enabled) and then is cleaved in the 
5’-3’ direction by XRN1 following decaping47,48,49. 
If, however, SMG7/SMG5 heterodimer is recruited, then its interaction with the 
phosphorylated UPF1 induces deadenylation, carried out by the PAN2/PAN3 and CCR4-
NOT complex; also, decaping by the action of DCP1/DCP2 takes place. This allows the 
transcript to be degraded in the 3’-5’ direction by the exosome and in the 5’-3’ direction 
by the exonuclease XRN132,50,51,52. 
Additionally, SMG7 and SMG6 recruit protein phosphatase 2a (PP2A), which induces UPF1 
dephosphorylation and dissociation, thereby allowing recycling for the next round of 
NMD53. The mRNA degradation via NMD pathway is simplified bellow on figure 5.  
 
 
Figure 5 – Simplified decay pathway of human NMD. UPF1 binds to the stalled ribosome 
through interaction with eRF3 and is subsequently phosphorylated. Phosphorylated UPF1 binds either 
SMG6 or the SMG5/SMG7 heterodimer. Binding of the endonuclease SMG6 results in RNA cleavage in 
the vicinity of the PTC, producing decay intermediates that will  be rapidly degraded in both 5’ -3’ (l ight 
blue PacMan) and 3’-5’ directions (violet PacMan) by exonucleases. On the other hand, binding of 
SMG5/SMG7 results in the recruitment of deadenylases (purple PacMan) and decaping enzymes (dark 
PacMan). After being both decapped and deadenylated, the RNA is degraded by exonucleases. In 




1.3.3. NMD Targets 
During recent years, it has been increasingly clear that NMD isn’t simply an mRNA quality 
control mechanism targeting nonsense mRNAs, as wide variety of physiological transcripts 
that don’t contain any PTC whatsoever are regulated by it54,55. In fact, studies have 
revealed that NMD participates in the control of steady-state levels of 3-10% of the 
transcriptome56. So the question arises: what renders these non-faulty mRNAs NMD-
sensitive? Some characteristics possessed by these NMD-sensitive transcripts include 
upstream ORFs (uORFs), long 3’UTRs or signals for programmed frameshift; mRNAs 
encoding proteins that contain selenocysteine, where the UGA codon is interpreted either 
as a stop codon or a PTC depending on selenium concentration; bicistronic mRNAs, among 
others33,57,58. Many of these aforementioned features make the stop codons of these 
mRNAs, called natural NMD targets, to be in a position where they are recognized as de 
facto PTCs by the NMD machinery, in spite of them being canonical ones.  NMD natural 
targets perform a variety of functions in the cell, ranging from regulation of alternative 
splicing to stress response and cell-cycle progression59,60. One of those natural NMD 
targets, which is important in this work, is HFE mRNA, whose gene, when mutated, might 
be involved in hereditary hemochromatosis, a disease of iron metabolism where an 
excessive intestinal iron absorption is present, leading to organ damage 59. 
 
1.3.4. NMD and Human Disease 
One can easily infer the clinical relevance of NMD from the fact that approximately one 
third of all human genetic disorders are attributable to PTCs, many of which are NMD 
targets29,61. There are several disease phenotypes that result from nonsense or frameshift 
mutations that are indeed modulated by NMD29,34. Examples of disease clinical phenotypes 
modulated by NMD include cystic fibrosis, Duchenne muscular dystrophy and β-
thalassemia, among others. 
In diseases where NMD is a clinical manifestation modulator, the surveillance mechanism 
impedes the nonsense mRNA to be translated into truncated proteins. These truncated 
proteins can have lost their function, have acquired a dominant-negative effect or gain of 
function, but they can also be still functional or residually functional and in those cases, it’s 
obvious that NMD, instead of protecting the cell against the deleterious effect of proteins 
resulting from faulty mRNAs, is in fact having a detrimental effect instead. So, NMD can 
either be beneficial or detrimental to the clinical manifestation of a given disease26,30. 
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Cystic fibrosis constitutes an example where NMD worsens the clinical outcome of a 
disease. Some truncated proteins encoded by the mutated CFTR gene partially retain 
normal function, however, NMD targets and degrades their PTC-containing mRNAs, 
thereby downregulating those proteins, which of course aggravates the clinical 
manifestations of the disease26,62. 
In β-thalassemia, on the other hand, NMD has the opposite effect; it has a well-
documented beneficial role. PTC-containing β-globin mRNAs are targeted and degraded by 
NMD and this prevents the synthesis of C-terminally truncated proteins toxic for the 
cell26,63. 
 
1.3.5. β-thalassemia as a Model 
The β-thalassemias comprise a heterogeneous group of inherited human anaemias, and 
are among the most common genetic diseases worldwide arising most frequently as a 
result of nonsense or frameshift mutations in the β-globin gene. It generally has a pattern 
of autosomal recessive inheritance, except when nonsense mutations occur on the last 
exon, being dominant in that case. The disease is characterized by reduced or absent β-
globin chains, which causes low levels of haemoglobin and reduced production of red 
blood cells64,65. 
Several nonsense mutations have been characterized for the β-globin gene, of with CD15, 
CD26 and CD39 are of particular importance for this study. In CD15-thalassemia the PTC, 
being on codon 15, is near the 3’-end of the transcript and this proximity to PABP will 
inhibit NMD, making this transcript produce a C-terminally truncated protein. In CD39-
thalassemia, however, there is no AUG-proximal effect and this PTC will elicit NMD66,67. 
The profusion of this disease in the world, the small size of the β-globin gene and the wide 
range of nonsense mutations that it can harbour, “reacting” in different ways to NMD, are 
all reasons that turn this genetic disorder a good model for studying this surveillance 
mechanism64,66. 
 
1.3.6. Nonsense Suppression Therapy 
In the most aggressive manifestation of β-thalassemia (Thalassemia Major) and in some 
phenotypes of Thalassemia Intermedia, patients require regular red blood cell transfusions 
and appropriate chelation therapy to counterbalance the iron overload often present due 
to those necessary transfusions. Bone marrow transplantation remains the only cure, but 
it doesn’t constitute by any means a true solid hope for patients, given the compatibility 
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issues and other risk factors like the extent of iron accumulation present at the time of 
transplantation. Given the fact that NMD is a modulator of the clinical manifestation of β-
thalassemia, it constitutes a promising and needed therapeutic strategy for this disease 
and many others caused by PTC-generating mutations that don’t have effective 
treatments22,33,64,68. At the current point in time, these therapies have already been 
analysed in clinical trials for Cystic Fibrosis and Duchenne’s muscular dystrophy69. 
In nonsense suppression therapy, one takes advantage of the fact that some truncated 
proteins arising from PTC-containing mRNAs are still functional but, however, they do elicit 
NMD and are therefore down-regulated. If this NMD eliciting could be hampered, then the 
protein would still be produced and hence at least phenotype amelioration of the disease 
would take place33,70. The way this is done is through the PTC “readthrough” strategy, 
which is the process that recodes a stop codon, in this case premature, into a sense codon, 
thereby allowing translation elongation to continue until the canonical stop codon is 
reached and a full-length protein is produced, which would otherwise be impossible70. 
Mechanistically, suppression therapy works by facilitating the ability of near-cognate 
aminoacyl tRNAs (tRNAs that are complementary for two of the three codon nucleotides)  
to be incorporated into the ribosomal A-site (figure 6), thereby effectively increasing the 
number of times a PTC will be read as a sense codon and a full -length protein is produced, 
restoring enough normal protein function in the cell 70. 
 
 
Figure 6 – Suppression of translation termination. From left to right, a near-cognate 
aminoacyl-tRNA complementary base pairs (at two of the three bases , of course) with the premature 
termination codon with the help of eEF1A. The aminoacid carried by this near-cognate tRNA is added to 
the growing polypeptide chain, translocation occurs and premature translation termination is aborted, 
taking place normal translation elongation instead, until  the canonical stop codon is eventually reached. 




The ribosomal readthrough is accomplished by the use of small molecular weight 
compounds, namely aminoglycoside antibiotics such us gentamicin and geneticin (G418), 
and also non-aminoglycoside compounds such as ataluren (PTC124). This drugs bind to the 
ribosomal decoding centre, decreasing the accuracy of complementary base pairing 
between codon and anticodon and, in this way, facilitates near-cognate aminoacyl-tRNA 
incorporation. Aminoglycosides have antibacterial activity, may cause cell toxicity and, at 
an organismal level, nephrotoxicity; PTC124, a non-aminoglycoside, on the other hand, is 
free from the previously mention disadvantages, however its effectiveness is controversial, 
with one study71 reporting that there is no evidence for PTC inducing readthrough, 
however, the majority of studies point to successful PTC readthrough in mammalian cells 
and it is currently undergoing clinical trials for several diseases33,70,72,73,74,75,76. 
Suppression therapy efficiency, besides being different for different compounds and 
depending on each individual, also depends on the PTC nature, the ranking order for 
aminoglycoside readthrough efficiency being UGA≥UAG>UAA; and PTC context: in this 
regard, the nucleotide immediately downstream of the PTC is the most important one, 
being the ranking order of readthrough efficiency according to the it, C>U>A>G, but up to 
6 nucleotides downstream and 2 nucleotides upstream of the PTC can have an effect on 
readthrough efficiency77,70,69. 
 
1.4. Nonstop mRNA Decay 
Nonstop decay is by far much less well understood than NMD and this lack of knowledge is 
even more apparent for human cells; a great amount of what is known for the process 
relates to yeasts. Nonstop decay has evolved as a surveillance mechanism that targets and 
degrades transcripts that lack an in-frame stop codon. These transcripts don’t allow 
normal translation termination to take place and instead the ribosome reads the ORF and 
into the 3’UTR, where it eventually stalls, as translation of poly(A) results in positively 
charged poly-lysine that interacts with the very negative exit channel of the ribosome ; as 
little as 6 incorporated lysine residues are enough to incite ribosome stalling8,78,79,80. 
Nonstop mRNAs can arise from nonstop or frameshift mutations in the DNA that disrupt 
the stop codon, instances when transcription aborts or even from cryptic poly(A) sites, 
which cause premature polyadenylation80,81,82. In particular, when cryptic poly(A) sites are 
present, upstream of the stop codon, these mRNAs can give rise to truncated proteins 
that, in similarity with NMD, can acquire deleterious dominant negative or gain of function 
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effects79,80,83. It is estimated that nonstop mRNAs can arise from premature 
polyadenylation 5-10% of the time83,84. However, there are many questions regarding the 
initial recognition of NSD-targeted ribosome complexes on a mechanistic level8. 
In yeasts, nonstop mRNA degradation probably starts when the Ski7 GTPase recognizes 
the stalled ribosome through its C-terminal domain, promoting transcript degradation by 
the exosome83,85. Ski7 belongs to a family of proteins that also includes the eukaryotic 
release factor 3 (eRF3) and the eukaryotic elongation factor eEF1α, however, Ski7 is 
different in two ways: it doesn’t act as an heterodimer and may not be dependent on GTP, 
which is an integral part of the specificity of both eRF3 and eEF1α86,87,85. Nonstop mRNA 
degradation, as it has already been previously mentioned, is accomplished by the 3’ -5’ 
exonucleolytic action of the exosome, without the need for prior deadenylation82. 
 
 
1.5. Eukaryotic Exosome 
The exosome, as well as its cytoplasmic factors are conserved in all eukaryotes 88,89. It is a 
3’-5’ multi-subunit ribonuclease complex of approximately 400 kDa, present in nuclear, 
cytoplasmic and nucleolar forms, whose main function is degrading almost every type of 
RNA in the cell, thereby guaranteeing the following: the degradation of RNA processing by-
products, elimination of aberrant transcripts in various mRNA surveillance pathways 
(including NMD and NSD), removal of incorrectly spliced mRNAs and it also prevents 
defective rRNA incorporation into the ribosome structure. Furthermore the exosome plays 
a role in RNA molecules maturation in the nucleus, such as ribosomal RNAs, for 
instance90,91,92,93. 
The eukaryotic exosome has a conserved structure constituted by a 9-subunit core, in 
similarity with bacterial PNPase and the archaeal exosome, which is made up of a 
hexameric ring and a “cap” consisting of three RNA-binding subunits (figure 7). Depending 
on the subcellular localization, to this 9-subunit core can bind Rrp44 (Ribosomal RNA 
Processing Protein) also known as Dis3, Rrp6, or both Rrp44 (Dis3) and Rrp6; it is possible 
that the exosome co-factors influence how a “binding path” is chosen (Rrp6 or Dis3) by 





Figure 7 – Eukaryotic exosome structures. On the left, we can see the cytoplasmic 10-
subunit exosome, at the centre it is pictured the canonical nuclear 11-subunit exosome and on the right, 
we have the nucleolar 10-subunit exosome. The 9-subunit core is present in all  three forms. In the 
figure, the red circles represent phosphorolytic and hydrolytic exoribonuclease active sites and the pale 
yellow circles represent endoribonuclease active sites. Adapted from Januszyk & Lima (2014).  
 
Dis3 is the largest subunit of the exosome (approximately 110 kDa) and the responsible for 
the major exoribonucleolytic activity of the complex. Dis3 is indispensable for cellular 
viability and is predominantly present in the nucleus, but also in the cytoplasm. Its 
structure consists of: an N-terminal pilus-forming N-terminus domain (PIN) with three 
aspartic acid residues; the PIN domain mediates the majority of the contacts with the N -
terminal of the Rrp41 subunit of the exosome core, so its main function is really to bind 
Dis3 to the core; two cold shock domains (CSD1 and CSD2) responsible for RNA-binding; 
central ribonuclease domain (RNB), which contains an active site for exoribonuclease 
activity; and a C-terminal S1 domain also responsible for RNA binding (figure 8). Dis3 binds 
both to Rrp41 and Rrp4594,95. 
 
 
Figure 8 – Model for Dis3 domains’ structure. On the left one can see the N-terminal 
exosome-binding domain, PIN, followed by the RNA-binding CDS domains. Next are the catalytic RNB 
site and the C-terminal RNA-binding S1 domain. In Tomecki et al. (2010). 
 
 
1.6. Human Dis3L2 
Recent studies indicate that human DisL2 (DIS3 Like 3'-5' Exoribonuclease 2) protein is a 
cytoplasmic processive 3’-5’ ribonuclease that contributes to RNA homeostasis and whose 
activity is independent to that of the exosome. Regarding its structure, it is known that it 
lacks a PIN domain, hence it not binding to the exosome. Furthermore, Dis3L2 doesn’t co-
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precipitate or co-localize with the exosome components. It also has an extended RNA-
binding CSD1 domain, which can explain Dis3L2’s stronger activity for structured 
substrates with short two nucleotide overhangs or blunt-ended double stranded RNA 
when compared to hDis396,97. Dis3L2 main targets constitute poly-urydilated transcripts 
(figure 9), being inhibited by poly(A) sequences, and it has recently been linked to 
apoptosis-triggered global RNA degradation, which involves 3’-urydilated 
intermediaries96,98. Transcript urydilation can trigger decaping and 5’-3’ degradation and 
protect 3’ ends from exoribonucleases; however, it can also  promote 3’-5’ degradation. 
This only makes sense because of the spatial separation between 5’ -3’ degradation and 
decaping, as well as Dis3L2 localization on docked structures to processing bodies (P-
bodies), which is where 5’-3’ degradation takes place in the eukaryotic cell ; even more, 
under stress conditions, Dis3L2 completely co-localizes with P-bodies, which can be a way 
of accelerating the degradation of urydilated RNAs96,97. Recently, human Dis3L2’s role in 
mRNA metabolism has been highlighted and it has been seen that it may well be essential 
for cell growth regulation and division, as its depletion causes mitotic abnormalities due to 
deregulation of mitotic control proteins, being associated with Perlman syndrome and 
susceptibility to Wilms tumor99; furthermore, it has a role in target directed miRNA 
degradation100. Weather Dis3L2 is coupled to NMD or NSD is still unclear. 
 
Figure 9 – mRNA degradation pathways in the cytoplasm of S. pombe. From left to 
right, mRNAs can de degraded in the 5’-3’ direction by Xrn1 exonuclease, in the P-bodies; in the 3’-5’ 
direction by Dis3L2 that can be localized on P-bodies or not; and again in the 3’-5’ direction by the 







The aims for this work are divided in two parts, corresponding to the two chapters of this 
dissertation. 
 
2.1. Chapter I 
β-thalassemia is one of the most common genetic diseases worldwide and its treatment 
can be bothersome and inconvenient, with no risk-free and easy to attain cure64,65,68. 
Furthermore, β-thalassemia happens mainly as a result of nonsense mRNAs committed to 
degradation by NMD; with NMD being a clinical modulator of the manifestations of this 
disorder, it constitutes a hope for new treatments26,63,101. Under that light, if one can use 
suppression therapy to induce PTC readthrough on the faulty mRNAs that trigger this 
disease, one would, in theory, be able to induce synthesis of full -length protein that could 
maintain normal physiological function. Already preliminary results in our lab have shown 
that G418 can suppress a PTC at codon 39 of the human β-globin mRNA, although at low 
levels in cultured erythroid cells; also, some recent studies have shown high readthrough 
efficiencies for a non-aminoglycoside compound, PTC12474,75,76. 
The aim for chapter I of this work was to test weather suppression therapy can restore 
enough β-globin to correct the manifestations of the disease and, under that light, we 
decided to test weather β15 (nonsense mutation CD15) or β39 (nonsense CD39) mutated 
versions of the HBB gene allow their suppression by either G418 or PTC124 to occur, in a 
dose-dependent manner, using for this effect HeLa cells transiently transfected with 
plasmids containing either the wild-type (βWT), β15 or β39 versions of the human β-globin 
gene. 
2.2.  Chapter II 
DIS3L2 is a novel 3’-5’ exonuclease independent of the exosome of which little is yet 
known, especially in humans96,97. Currently it is known that this protein has a preference 
for poly-urydilated transcripts, but either if this protein is linked to the degradation 
coupled to surveillance mechanisms or just to global urydilated mRNA is yet to be 
known96,97,98,99. Also, recently, mutations in the germline DIS3L2 gene have been linked to 
mitotic abnormalities and human diseases99. Given the fact that surveillance mechanisms 
are vital to the cell and are involved in many human diseases, and taking into account the 
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possible important role in human disease and the current gap in the knowledge regarding 
hDis3L2, it would be of interest investigate if this protein is involved in the degradation 
coupled to surveillance mechanisms, augmenting the overall knowledge of mRNA 
metabolism. 
The aim for the chapter II of this work was to investigate if hDis3L2 is i nvolved in the NMD 
and/or NSD mRNA degradation, as well as normal transcript degradation. To this effect, 
we utilized a knockdown approach using siRNAs specific to hDis3L2 in HeLa cells 
transiently transfected with plasmids containing either the βWT, β15¸ β26, β39 or βNS (a 






















3. MATERIALS AND METHODS 
_______________________________________________________________________ 
3.1. Plasmid Constructs 
The plasmids containing βWT (wild type version of the β-globin gene), β15 (with nonsense 
mutation at codon 15) [CD 15 (TGG→TGA)], β26 (with nonsense mutation at codon 26) [CD 
26 (GAG→TAG)], β39 (with nonsense mutation at codon 39) [CD 39 (CAG→TAG)], or βNS 
(without the canonical stop codon) of the human β-globin gene were obtained as 
previously described in Silva et al. (2006). All variants were created within the 428-bp 
NcoI-BamHI fragment of the β-globin gene template by overlap-extension PCR. Competent 
Escherichia coli were transformed with the plasmid DNA, and transformants were selected 
on luria-bertani (LB) agar/ampicillin plates. The corresponding plasmid DNAs were purified 
from overnight cultures of single colonies with the NZYMini prep kit (NZYTech, Portugal) 
following the manufacturer’s instructions. Confirmation of the correct cloned sequences 
containing the relevant mutation was carried out by automatic sequencing.  
 
3.2. Cell Culture and Plasmid Transfections 
HeLa cells were grown in Dulbecco’s modified Eagle’s medium (DMEM 1x + GlutaMAXTM-
I; Gibco® by Life Technologies™, USA) supplemented with 10% (v/v) foetal bovine serum 
(FBS; Gibco® by Life Technologies™, USA), incubated at 37°C in a humidified atmosphere of 
5% CO2. 
Transient transfections were performed using Lipofectamine 2000 Transfection Reagent 
(Invitrogen® by Life Technologies™, USA), following the manufacturer’s  instructions, in 35-
mm plates containing HeLa cells plated 24h prior to transfection, using 200 ng, of plasmid 
DNA of each variant (βWT, β15 or β39). Cells were lysed, 24h after transfection, via 
solubilisation in Passive Lysis Buffer (PLB; Promega, USA)  for posterior protein analysis. 
 
3.3. Knockdown Experiments 
HeLa cells were plated into P-60mm cell plates to a concentration of approximately 
100x103 cells/mL and 24h later, the cells were transfected with the siRNAs to a final 
concentration of 20nM using Lipofectamine 2000 Transfection Reagent (Invitrogen® by 
Life Technologies™, USA), following the manufacturer’s instructions . Approximately 36h 
later, a second siRNA transfection was performed in the same way as the first one and, at 
the same time, the cells were transiently transfected with 400ng of the plasmid containing 
the respective variant (βWT, β15, β26, β39 and βNS) using Lipofectamine 2000 
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Transfection Reagent (Invitrogen® by Life Technologies™, USA), following the 
manufacturer’s instructions. Cells were lysed, 24h after this last transfection, by 
solubilisation in RA1 Buffer (NZYTech, Portugal) for posterior RNA isolation.  
 
3.4. RNA isolation 
Total RNA from cultured HeLa cells was isolated using the RNA extraction kit NucleoSpin 
RNA II (Macherey-Nagel, Germany) according to the manufacturer’s instructions. RNA 
samples were treated with RNase-free DNase I (Ambion® by Life Technologies™, USA). 
 
3.5.  Reverse transcription-coupled quantitative PCR (RT-qPCR)  
cDNA synthesis was carried out using 2 μg of total RNA and Reverse Transcriptase 
(NZYTech, Portugal), according to the manufacturer’s instructions. Real -Time quantitative 
PCR (RT-qPCR) was performed in ABI Prism 7000 Sequence Detection System, using 
SybrGreen Master Mix (Applied Biosystems® by Life Technologies™, USA). Primers specific 
for the gene of interest, β-globin (primer forward 5’-CTCAAGGGCACCTTTGCCAC-3’ and 
primer reverse 5’-CAGCACACAGACCAGCACGT-3’) and for the control, luciferase reporter 
gene were used. Quantification was performed using the relative standard curve method 
(ΔΔCt, Applied Biosystems® by Life Technologies™, USA). The following cycling parameters 
were used for the cDNA synthesis: 10 min at 25°C, then 50°C for 40 min and 5 min at 85°C. 
Technical triplicates from each experiment were assessed in all cases.  
 
3.6.  SDS-PAGE and Western Blotting 
Cells lysates were denatured for 10 minutes at 95°C. Five μl of SDS sample buffer 5x 
[Bromophenol blue (0.25%), DTT (dithiothreitol; 0.5 M), Glycerol (50%), SDS (sodium 
dodecyl sulfate; 10%), Tris-Cl (0.25 M, pH 6.8)] was added to 20 μl of purified lysates and 
these were loaded into a 12% polyacrylamide gel and resolved for 1 hour. Afterwards, they 
were transferred to a PVDF membrane (Bio-Rad, USA) at 30V for 30minutes. The 
membranes were then either fixated with a 0,4% PFA (v/v) solution in PBS 1x (Phosphate  
Buffer Saline) for 30min at room temperature and blocked in TBS 5% (w/v) non-fat dry 
milk for 1 hour, or immediately blocked in SuperBlockTM Blocking Buffer (ThermoFisher 
Scientific, USA). Membranes were probed using mouse anti-α-tubulin antibody (loading 
control; Roche, Switzerland) at 1:10 000 dilution and mouse monoclonal anti -β-globin 
(Santa Cruz Biotechnology, USA) at 1:200 overnight. After incubation with the primary 
antibody, membranes were washed 3 times in TBS 1x. Detection was carried out by 
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incubating the membranes for 1 hour with the secondary antibodies, peroxidise -
conjugated anti-mouse IgG (Bio-Rad, USA), anti-rabbit IgG (Bio-Rad, USA) antibodies, 
followed by enhanced chemiluminescence reaction. 
 
3.7. SOEing PCR 
SOEing (Gene Splicing by Overlap Extension) PCR: four SOEing PCRs were required in order 
to extract the FLAG sequence 
(GACTACAAGGATGACGATGACAAAGACTACAAGGATGACGATGACAAA) from pTRE+mTOR 
plasmid to pTRE2pur+(β-globin variant). The first three SOEings were carried out using the 
following conditions: 5 μL Pfu Buffer 10x, 5 μL DMSO 100%, 1 μL MgSO4, 5μL dNTPs 
(2mM), 0,85μL BSA, 1μL Pfu enzyme, 2μL of each primer (forward and reverse) and 1μL 
template DNA and water to the final volume of 50 μL. The cycling program was: 95oC 
during 4min30sec.; 40 cycles of 95oC 1min, 54oC 30sec., 72oC 1min.; and 72oC 10min. 
The final SOEing4 was carried out using a final reaction volume of 100 μL, seeing that 15 μL 
of that volume was the template DNA (4 μL of SOEing1 PCR reaction, 8 μL of SOEing2 and 3 
μL of SOEing 3, respecting equimolar concentrations). The sequence of these primers is 
listed in Annex I.  
 
3.8. Digestions and Ligation Reactions 
Following purification form the agarose gel using the NZYGelpure kit (NZY-Tech, Portugal), 
following the manufacturers’ instructions, 6,5μL of SOEing4 PCR product reaction was 
submitted to an A-tailing reaction following the manufacturer’s instructions in NZY-A PCR 
cloning kit (NZYTech Potugal). After A-tailing, ligation was performed using T4 DNA Ligase 
and a proportion of 1 part vector to 3 parts fragment in a 10μL final volume at 4oC 
overweekend following the manufacturer’s instructions in the NZY-A PCR cloning kit. 
Following that, digestion of the ligation product was performed with the enzymes BstXI (10 
U/µL) (Thermo Scientific) and BspLU11I (10 U/µL) for 2 hours at 37oC. We used the volume 
corresponding to 2μg of the ligation product, 1μL of each enzyme, 5μL of Buffer3 (100mM 





3.9. Statistical Analysis 
Results are expressed as mean ± standard deviation of 3 experiments in which the mRNA 
levels expressed from β15, β26, β39 and βNS-containing plasmids are normalized to the 
mRNA levels of the βWT transfected with siRNA for Luciferase, which are arbitrarily set to 
1. Student’s t test was used for estimation of statistical significance (unpaired, two-tailed). 
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4. RESULTS & DISCUSSION 
_______________________________________________________________________ 
 
4.1. Human β-globin protein wasn’t detectable by western blot analysis 
SDS-PAGE Western blot analysis of protein samples extracted from HeLa cells transfected 
with each one of the pTRE+(β-globin variant) plasmids, or not transfected at all (NT), was 
performed in order to evaluate protein levels produced by each transcript (fig. 10). Also, 
one of the membranes was blocked using SuperBlock solution, while the other was 
blocked with TBS-milk 5% as usual and incubated with a protein fixation solution (PBS-PFA 
0,4%). We wanted to test this protocol with a fixation solution because as β-globin is a 
small protein, it could be that it got washed away easily from the membrane. 
As one can observe the figure bellow, no significant difference was produced by either 
using a fixation solution or not. Furthermore, one can see that α-tubulin was detected in 
both membranes but not β-globin. As the antibody used for β-globin had already been 
previously tested in the lab with the same negative result even with posterior optimization 
of the western blot protocol, we decided to make changes that hadn’t yet been tested.  
We hypothesized that β-globin was being lost in the transfer process. Hence, we repeated 
western blot analysis of the cell lysates adjusting the polyacrylamide gel percentage to 
14%, transferring just for 30 minutes at 30V in a cold room using a transfer buffer without 
SDS, because small proteins are more likely to be hindered by this deterge nt from binding 
to PVDF membranes; we also performed every washing and blocking step using TBS 
without Tween 20 or any other detergent. However, the results were no different from 








Figure 10 – Western blot analysis of cell lysates. The molecular weights of the α-tubulin 
(55 kDa) and β-globin (16 kDa) proteins are indicated on the right hand side of the autoradiographs. 
Below each autoradiograph, there is the indication of whether that membrane went through a fixation 
procedure (PFA 0,4% solution) or if it was just blocked using a commercial solution (SuperBlock 
solution). NT indicates the non-transfected cell  lysate. 
    NT        βWT       β15       β39    NT         βWT       β15       β39  
α-tubulin (55 kDa) 
β-globin (16 kDa) 





In order to still be able to detect β-globin, we then approached the problem in another 
way: we tried to clone a tag at the C-terminal region of the β-globin sequence for which 
we had a working antibody in the laboratory.   
 
 
4.2. SOEing PCR was not successful enough as an approach to clone a    
FLAG-tag into the C-terminal region of Human β-globin 
We used the Gene Splicing by Overlap extension PCR technique in order to clone the FLAG-
tag sequence at the C-terminal end of the β-globin sequence as we already had a 
functioning antibody for FLAG and also we had FLAG already cloned into another plasmid 
in the laboratory (pTRE+mTOR), which made this the fastest option. FLAG consists of two 
repeats of 5’-GACTACAAGGATGACGATGACAAA-3’ sequence. 
Our strategy consisted of taking FLAG from the plasmid it was located in and place it in the 
C-terminal region of the β-globin sequence previously cloned in pTRE2pur vector. For this 
we designed and utilized specific primers whose sequences are present in table 1 in Annex 
I. In our so-called SOEing 1, we used a specific reverse primer for the C-terminal region of 
the β-globin sequence containing a linker sequence to the FLAG (that is located, as 
previously mentioned, in other plasmid), as well as a forward primer for β-globin; the PCR 
product contains the BstXI restriction site (figure 11A and 13A) for posterior digestion. In 
SOEing 2, we used a specific forward primer for the 5’ end region of the FLAG sequence 
with a linker sequence to β-globin (that is located in other plasmid, pTRE2pur), as well as a 
reverse primer for the 3’ end of the FLAG sequence containing a linker sequence for the 
3’UTR of the β-globin sequence with a termination codon (TAA) immediately 3’ of the 
FLAG sequence (figure 11B and 13A). In SOEing 3, we used a specific forward primer for 
the 3’UTR of the β-globin sequence containing a linker sequence for the FLAG along with a 
TAA termination codon just 3’ of the linker, as well as a reverse primer for the pTRE 
plasmid sequence that contains the BspLU11I enzyme restriction site (figure 11C and 13A). 
Our objective with these three SOEing ractions was to get our insert (FLAG-tag), which will 
be present in the SOEing 2 PCR reaction and create overlap regions (with the linker 
sequences) in the other two PCR products (which contain the 3’ end region of the β-globin 
gene in SOEing 1 and the 3’UTR region in SOEing 2) to the FLAG sequence thereby 
tethering the FLAG-tag to the C-terminal region of the β-globin gene with a final SOEing 
PCR 4 where we would add together in equimolar proportions the products from previous 
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SOEings and amplify them with the two most external primers (the forward primer of 
SOEing 1 and the reverse primer of the SOEing 3) (figure 12 and 13B and C). This would 
allow us, by the use of a FLAG-specific primary antibody, to effectively verify if PTC 
readthrough had occurred in transfected HeLa cells with the β-globin variants treated with 
G418 or PTC124 drugs. 
 
Following SOEing 1, 2 and 3 reactions, the PCR products were resolved in an agarose gel 
(figure 13A) and subjected to column purification to be then utilized in the SOEing 4 
reaction (figure 13B). However, as one can see from figure 13B, the expected SOEing 4 
band didn’t appear, which goes to show that indeed much is lost during the purification 
process. We therefore tried performing the SOEing 4 reaction with the direct un-resolved 
and un-purified products of the previous SOEings (figure 13C). As one can clearly see, this 
time, our SOEing 4 band did appear, although, predictably, with many other unspecific 
products. 
Figure 11 – Ilustrations for SOEing PCR 1, 2 and 3. On panel A one can see the model for SOEing 1. In this 
model, the pTRE plasmid sequences are represented as a bold black l ine, the 5’ and 3’ UTRs are shown in gray and β-
globin in red. On panel B there’s the model for SOEing 2, where the 5’UTR of the mTOR sequence is represented in gray, 
the mTOR sequence itself in blue and the FLAG sequence in yellow. On panel C SOEing3 is schematized. In the figure, the 
asterisks represent enzyme restriction sites and the arrows represent the primers and their amplification direction; the 
stronger ends of some primers represent the linker sequences, they are elevated as a way to show that they are not 






Figure 12 – Model for SOEing 4 PCR and Ligation to pTRE vectors. On panel A one can 
see the products from previous SOEings 1, 2 and 3; after the PCR reaction takes place and digestion is 
performed on the product, which is represented by the grey arrow, we are left with our final insert, 
which contains part of the 3’ region of the β-globin gene (in red), followed by the FLAG-tag sequence (in 
yellow), the canonical stop codon (that is represented as a red 4-pointed star) and finally the 3’UTR of β-
globin as well as some plasmid sequences (bold black l ine). The asterisks represent enzyme restriction 
sites. On panel B, l igation of the digested SOEing 4 product to the digested pTRE vector containing a β-
globin gene variant is schematized. After l igation takes place, represented by the grey arrow, we have 
our final product. The green arrows on the bottom show the areas where ligation by T4 DNA ligase took 
place. The primers are not represented here because they could only be the most exterior ones. 
 
We tried to optimize the SOEing 4 PCR reaction by changing the concentrations of its 
components and even having performed the PCR at various annealing temperatures so 
that the better one could be chosen. However, no significant differences in efficiency were 
obtained. The intended SOEing 4 product band was purified from the gel, digested using 
BstXI and BspLU11I enzymes, and this digestion was run on a gel and the intended product 
purified, which was then ligated to a commercial plasmid pNZY28-A using A tailing and T4 
DNA Ligase and amplified through bacterial transformation, this in order to have an 
acceptable quantity of our product, despite the successive purifications . Grown colonies 
were selected and its DNA digested with BstXI and BspLU11I and run on an agarose  gel. As 
one can see from figure 14, the enzyme BspLU11I cuts our template DNA at more than one 
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site, but still that doesn’t invalidate our result. Only one colony selected presented a band 
that had the possibility of containing our product, the last one loaded on the gel.   
  
 
Figure 13 – Gel Electrophoresis of the SOEing PCR reactions’ products. On panel A 
one can see SOEing 1, 2 and 3, 10µL of each reaction product was loaded and resolved i n an agarose gel. 
S1 stands for SOEing 1 PCR reaction product, S2 for SOEing 2 PCR and so on. SOEing 1 PCR product is 
118bp long, SOEing 2’s is 57bp and SOEing 3’s is 413 bp. “-“ stands for negative control , which consisted 
of the PCR mix reaction only, without any template DNA. On panel B one can see the electrophoresis  of 
the SOEing 4 reaction product that was performed using the purified products of SOEings 1, 2 and 3 
from panel A. The + symbol represents the positive control, which was the product of a PCR reaction 
using the same primers as in SOEing 4 but with the pTRE2pur carrying human β-globin as a template. 
Samples were resolved in an agarose gel. The positive control (+) consists of a PCR using pTRE βWT as a 
template for the SOEing 4 primers. SOEing 4 PCR product length is 571 bp. Panel C depicts the same 
procedure as panel B, with the exception that, this time, SOEing4 PCR was carried out with the direct un -













We then extracted the DNA band of interest, purified it and sequenced it. It did contain 
the FLAG sequence in the expected location, but unfortunately, something wrong must’ve 
occurred in the PCR reactions because what we obtained was the two FLAG repetitions 
with, however, other small sequences of the β-globin gene inserted between them. For 
this reason, we couldn’t use it for our experiments. 
We retried this approach several times but we never succeeded.  We think that the main 
problem lies in the SOEing 4 PCR reaction, for it has too many nonspecif ic products and 
also because the sizes of the different sequences are very dissimilar among them, which 
makes it difficult to have an equilibrium that makes our intended product the most 





Figure 14 – Gel electrophoresis of the colony PCR products. Digested (with BstXI and 
BspLU11I) DNA from the selected bacterial colonies transformed with pNZY28 -A + SOEing 4 l igation product 
was resolved in a 0,8% agarose gel . “-“ stands for negative control , where the PCR mix without any template 
was loaded and the + sign designates the positive control, which was the same PCR a s the others but with 





5. FINAL CONSIDERATIONS & FUTURE DIRECTIONS 
_______________________________________________________________________ 
 
Given the challenges we faced for Chapter I of this work, we couldn’t test weather 
suppression therapy can restore enough β-globin to correct the manifestations of β-
thalassemia. It would be easier as a future approach to carry out this study using a 
different primary antibody for human β-globin, since the other strategies involving cloning 
were demonstrated to be of difficult achievement and to take too much time. 
It could also be interesting, as an augmentation to the suppression therapy assays using 
G418 or PTC124, to test the same readthrough efficiency under NMD inhibiting conditions. 
These two treatments taken together could yield a stronger efficiency and there fore 
constitute a promising therapeutic strategy to treat β-thalassemia and other diseases 
caused by NMD eliciting nonsense mutations. This could be done taking advantage of the 
previous knowledge our lab and others4,38 that tethering PABPC1 in close proximity of a 
NMD-competent PTC inhibits NMD, transfecting cells with antisense oligonucleotides 
specific for the β-globin mRNA sequence, but with a degenerated poly(A)-tail, thus 
inhibiting UPF1 interaction with eRF3 and inhibiting NMD.  
Also, it would be interesting, following confirmation of our assumptions in HeLa cells, to 
make the same experiments in Murine Erythroleukemia (MEL) cells as expression models, 
as they differentiate into erythroid cells and thus provide a model closer to reality for the 
human β-globin gene, further strengthening the results102. Also, western blot analysis 






















































































4. RESULTS & DISCUSSION 
_______________________________________________________________________ 
 
4.1. DIS3L2 knockdown correlates with increased levels of β-globin 
mRNAs independently from their decay mechanism 
We transfected HeLa cells with plasmids expressing βWT, β15, β26, β39 or βNS gene 
variants of the human β-globin gene. Twenty-four hours later, cell cultures were either 
treated with siRNA for hDIS3L2 or Luciferase (LUC) as negative control. The β-globin mRNA 
levels were quantified by RT-qPCR analysis (figure 15). 
 
Figure 15 – RT-qPCR analysis of Dis3L2 knockdown experiments performed for 
the Human β-globin gene. The analysis was done on RNA isolated from HeLa cells containing the 
β-globin variants’ transcripts treated with either siRNA specific for Dis3L2 (siDIS3L2) or for the control, 
Luciferase reporter gene (siLUC). The bars represent the relative mRNA levels. Standard deviations are 
represented as vertical error bars. The p-values of the statistically significant differences are given above 
each pair of data. 
 
These results suggest that when Dis3L2 is present at low levels in the cell, mRNA decay is 
not as efficient, as evidenced by the fact that β39 mRNA is up-regulated with Dis3L2 
knockdown compared to normal Dis3L2 levels, this being statistically significant 
(p=0,0354). Furthermore, this happens independently of the decay mechanism, for the 
same happens, with a statistically significant difference, among variants that undergo NSD 
(βNS) (p=0,0286) or just normal transcript degradation (β15) (p=0,0289). However we 
didn’t obtain a statistically significant difference for βWT and β26. Those could be 
explained by the high standard deviations, but even in these conditions, we see a tendency 
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for mRNA levels to rise with Dis3L2 knockdown. hDis3L2’s role in mRNA degradation has 
already been established96,97, our results further contribute to assert this proteins ’ 
effective role in mRNA metabolism and, furthermore, point to the direction that it may be 
an ubiquitous degrading component, present in normal transcript degradation but also in 
surveillance mechanism directed decay. 
 
4.2. hDIS3L2 knockdown correlates with increased HFE mRNA levels 
In order to have further confirmation that Dis3L2 is involved in the NMD directed decay 
pathway, we decided to evaluate the expression of a known NMD target, the HFE (human 
hemochromatosis protein) mRNA. We did this experiment for two groups, the first one 
where we performed knockdown of Dis3L2 and the other where the knockdown target 
was UPF1 mRNA. Knowing that UPF1 is a key factor in the NMD pathway, this group 
constituted in fact a positive control for the experiment, where we expected NMD 
inhibition and consequent rise in HFE mRNA levels. 
 
Figure 16 – RT-qPCR analysis of Dis3L2 or UPF1 knockdown experiments 
performed for the HFE gene. The analysis was done on RNA isolated from HeLa cells containing 
the β-globin variants’ transcripts divided in two groups. In the first group, represented as darker in 
shade, cells were either treated with siRNA specific for Dis3L2 (siDIS3L2) or for the control Luciferase 
reporter gene (siLUC); in the second group, cells were treated with siRNA specific for UPF1 (siUPF1) or 
for the control Luciferase reporter gene once again. Standard deviations are represented as vertical 
error bars. The p-values of the statistically significant differences are given above each pair of data. 
 
As one can see in figure 16, the expected rise in HFE mRNA levels did occur when UPF1 
was silenced, and that difference is statistically significant. This is in accordance with 
previous results from our lab that indicate that HFE mRNA is an NMD natural target59. 
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That’s because, if NMD is inhibited, HFE mRNA levels will rise as they are targeted by the 
NMD machinery; hence HFE mRNA higher levels are an indicator of NMD inhibition. 
More importantly, though, Dis3L2 knockdown correlated with increased HFE mRNA levels 
with a statistically significant difference. As higher HFE mRNA levels indicate NMD 
inhibition, this means that when human Dis3L2 was silenced, NMD was in some way 
inhibited. These results further point to the assumption that human Dis3L2 is indeed 
involved in the NMD pathway, possibly being one of the recruited components for 
degradation of detected nonsense transcripts. Furthermore, the fact that the rise in HFE 
mRNA levels was significantly less than that observed for UPF1 mRNA, suggests that UPF1 
is more vital to NMD function than Dis3L2. In  fact, UPF1 is required for NMD 
triggering61,31,29,42. So one can deduce that hDis3L2 takes part in NMD but it isn’t, by any 























5. FINAL CONSIDERATIONS & FUTURE DIRECTIONS 
_______________________________________________________________________ 
 
Our results allow us to conclude that hDis3L2 protein is involved in surveillance 
mechanisms directed mRNA decay, namely NMD and NSD, but also possibly normal 
transcript degradation overall. However, further confirmation is needed. With this, our 
work contributes to the narrowing of the gap in the knowledge of the functions of this 
protein in human cells. 
As a practical measure, it would be of interest to further repeat the real time PCRs for the 
hDis3L2 knockdown experiments, as a means to tackle the big standard deviations present 
in the wild-type and β26 samples and by doing so, effectively asserting this work’s results. 
Also, other NMD natural targets could be used in place of HFE, such as SMG5, SLC7A11 and 
GADD45A as a way to diversify and give a stronger certainty for the Dis3L2 involvement in 
the NMD pathway. 
It would also be interesting to enrich the results, in a later phase, by looking for and using 
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Annex I – Primer sequences for the FLAG-tag cloning SOEing PCRs and the respective 
length of the reactions products. 
 
SOEing PCR number Primer forward 
(5’ – 3’) 
Primer reverse 
(5’ – 3’) 
Product length 
(base pairs) 
1 CAACGTGCTGGTCTGTG
TG 
CTTGTAGTCGTGATACTT
GTGGGCCAGGGC 
118 bp 
2 AAGTATCACGACTACAA
GGATGACGATGAC 
GCGAGCTTATTTGTCAT
CGTCATCCTTGTA 
57 bp 
3 GATGACAAATAAGCTCG
CTTTCTTGCTGTC 
TATGGAAAAACGCCAGC
AAC 
413 bp 
4 CAACGTGCTGGTCTGTG
TG 
TATGGAAAAACGCCAGC
AAC 
571 bp 
 
